Literature DB >> 2895910

Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

.   

Abstract

We report the preliminary 3-month outcome of a multicenter randomized trial of cryotherapy for treatment of retinopathy of prematurity (ROP). Transscleral cryotherapy to the avascular retina was applied to one randomly selected eye when there was threshold disease (defined as five or more contiguous or eight cumulative 30 degree sectors [clock hours] of stage 3 ROP in zone 1 or 2 in the presence of "plus" disease). An unfavorable outcome was defined as posterior retinal detachment, retinal fold involving the macula, or retrolental tissue. At this writing, 172 infants had been examined 3 months after randomization. An unfavorable outcome was significantly less frequent in the eyes undergoing cryotherapy (21.8%) compared with the untreated eyes (43%). While the surgery was stressful, no unexpected complications occurred during or following treatment. These data support the efficacy of cryotherapy in reducing by approximately one half the risk of unfavorable retinal outcome from threshold ROP.

Entities:  

Mesh:

Year:  1988        PMID: 2895910

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  32 in total

1.  Screening for retinopathy of prematurity.

Authors:  L Andruscavage; D J Weissgold
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

2.  Final visual acuity results in the early treatment for retinopathy of prematurity study.

Authors:  William V Good; Robert J Hardy; Velma Dobson; Earl A Palmer; Dale L Phelps; Betty Tung; Maryann Redford
Journal:  Arch Ophthalmol       Date:  2010-04-12

3.  Dealing with inter-expert variability in retinopathy of prematurity: A machine learning approach.

Authors:  V Bolón-Canedo; E Ataer-Cansizoglu; D Erdogmus; J Kalpathy-Cramer; O Fontenla-Romero; A Alonso-Betanzos; M F Chiang
Journal:  Comput Methods Programs Biomed       Date:  2015-06-16       Impact factor: 5.428

4.  Color fundus photography versus fluorescein angiography in identification of the macular center and zone in retinopathy of prematurity.

Authors:  Samir N Patel; Michael A Klufas; Michael C Ryan; Karyn E Jonas; Susan Ostmo; Maria Ana Martinez-Castellanos; Audina M Berrocal; Michael F Chiang; R V Paul Chan
Journal:  Am J Ophthalmol       Date:  2015-01-28       Impact factor: 5.258

5.  Pain score assessment in babies undergoing laser treatment for retinopathy of prematurity under sub-tenon anaesthesia.

Authors:  E S Novitskaya; V Kostakis; S C Broster; L E Allen
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

Review 6.  Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life.

Authors:  Przemyslaw Sapieha; Jean-Sebastien Joyal; José Carlos Rivera; Elsa Kermorvant-Duchemin; Florian Sennlaub; Pierre Hardy; Pierre Lachapelle; Sylvain Chemtob
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

Review 7.  Imaging in Retinopathy of Prematurity.

Authors:  N Valikodath; E Cole; M F Chiang; J P Campbell; R V P Chan
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Mar-Apr

8.  Screening for retinopathy of prematurity after surfactant treatment.

Authors:  D Brunner-Di Pietro; E Bossi; F Koerner
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

Review 9.  The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment.

Authors:  Lois E Smith; Anna-Lena Hard; Ann Hellström
Journal:  Clin Perinatol       Date:  2013-06       Impact factor: 3.430

10.  The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP).

Authors:  Joao Borges Fortes Filho; Gabriela Unchalo Eckert; Fabiana Borba Valiatti; Paula Gabriela Batista Dos Santos; Marlene Coelho da Costa; Renato Soibelmann Procianoy
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.